H. Saber

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

Sorafenib for theTreatment of Advanced Renal Cell Carcinoma

R. Pazdur, D. Morse, R. Justice, 2006 .

An FDA oncology analysis of immune activating products and first-in-human dose selection.

M. Manning, J. Leighton, H. Saber, 2016, Regulatory toxicology and pharmacology : RTP.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Pazdur, A. Al-Hakim, R. Justice, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

C. Garnett, L. Burke, R. Pazdur, 2012, Clinical Cancer Research.

An FDA oncology analysis of antibody-drug conjugates.

J. Leighton, H. Saber, 2015, Regulatory toxicology and pharmacology : RTP.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Antibody–Drug Conjugate Development

A. Khandelwal, Hong Zhao, H. Saber, 2013 .

FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease

R. Pazdur, R. Justice, Liang Zhao, 2015, Clinical Cancer Research.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates.

J. Leighton, H. Saber, Tiffany K Ricks, 2019, Regulatory toxicology and pharmacology : RTP.

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

J. Fourie, R. Pazdur, R. Justice, 2010, Oncology.

An FDA oncology analysis of CD3 bispecific constructs and first‐in‐human dose selection

J. Leighton, P. D. Del Valle, H. Saber, 2017, Regulatory toxicology and pharmacology : RTP.

Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

R. Pazdur, R. Justice, R. Sridhara, 2006, Clinical Cancer Research.

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

Lei Nie, Dhananjay D. Marathe, Richard Pazdur, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

R. Pazdur, M. Rothmann, C. Ko, 2014, The oncologist.

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

R. Pazdur, R. Justice, C. Ko, 2014, Clinical Cancer Research.

An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.

R. Pazdur, G. Reaman, J. Leighton, 2016, Regulatory toxicology and pharmacology : RTP.

Trends in the approval of cancer therapies by the FDA in the twenty-first century

R. Pazdur, G. Pamuk, J. Beaver, 2023, Nature Reviews Drug Discovery.

Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective.

R. Pazdur, Geoffrey Kim, P. Kluetz, 2017, International journal of radiation oncology, biology, physics.

Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop

G L Finch, M. Tabrizi, L. Kinter, 2008, International journal of toxicology.